The LAM Foundation Report issue

Foundation Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2002
NCT00457808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

The LAM Foundation

Active Ingredients

Drugs in Phase 3 Trials (1)

sirolimus (rapamune) (2 trials)

Drugs in Phase 2 Trials (1)

simvastatin (zocor) (1 trial)

Drugs in Phase 1 Trials (1)

l-glutamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphangioleiomyomatosis (Phase 3)

Sclerosis (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3